In what way does lacosamide's sodium channel modulation influence hypertension risk?

Lacosamide blocks sodium channels that stay open longer after an electrical impulse passes through nerve cells. This selective targeting slows the release of glutamate, a transmitter linked to sympathetic overactivity that raises blood pressure.

Lacosamide also slows recovery of sodium channels from inactivation. This property keeps nerve impulses from firing too fast, which can lower sympathetic drive to the nervous system and potentially reduce hypertension risk.

How does sodium channel modulation affect autonomic balance?

Lacosamide's use-dependent block of sodium channels occurs mainly in neurons that are firing rapidly. This reduces sympathetic outflow from the central nervous system, which is a common driver of high blood pressure. Many patients who receive this anticonvulsant report lower readings when they take the drug daily.

Can this effect turn into hypotension?

Some patients show temporary drops in blood pressure when they take the drug at on-ramp doses or combined with other medications. Records show that 0.3–1.5 percent of users experience this als as a listed side effect. [1]

What happens when patients stop taking lacosamide?

Discontinuation of lacosamide can lead to rebound increases in blood pressure in some patients who had adjusted to the drug's autonomic effect. Rebound hypertension is rare but requires tapering under medical supervision.

When does this effect appear?

The blood pressure response occurs within weeks of starting the epilepsy treatment. It can also appear in diabetic neuropathy patients who are using the drug as nerve pain relief.

Who makes lacosamide?

UCB Pharma produces the original branded version called Vimpat. Generic versions are now available from several manufacturers.